Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kura Oncology (KURA) Receivables - Accured (2022 - 2026)

Kura Oncology has reported Receivables - Accured over the past 5 years, most recently at $4.3 million for Q1 2026.

  • Quarterly Receivables - Accured rose 10.26% to $4.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Mar 2026, up 10.26% year-over-year, with the annual reading at $3.8 million for FY2025, 15.15% up from the prior year.
  • Receivables - Accured was $4.3 million for Q1 2026 at Kura Oncology, up from $3.8 million in the prior quarter.
  • Over five years, Receivables - Accured peaked at $4.3 million in Q1 2026 and troughed at $900000.0 in Q4 2022.
  • The 5-year median for Receivables - Accured is $1.9 million (2024), against an average of $2.3 million.
  • Year-over-year, Receivables - Accured skyrocketed 200.0% in 2024 and then grew 10.26% in 2026.
  • A 5-year view of Receivables - Accured shows it stood at $900000.0 in 2022, then increased by 22.22% to $1.1 million in 2023, then skyrocketed by 200.0% to $3.3 million in 2024, then rose by 15.15% to $3.8 million in 2025, then grew by 13.16% to $4.3 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Receivables - Accured are $4.3 million (Q1 2026), $3.8 million (Q4 2025), and $3.3 million (Q3 2025).